In Vivo is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nektar UK

Division of Nektar Therapeutics
www.nektar.com

Latest From Nektar UK

Drug Delivery: Moving from Platform to Product

The traditional drug-delivery business model of service for hire has fallen from popularity. Big Pharmas are doing few deals of this sort, and investors want bigger returns than fees and royalties can provide. Start-ups with drug delivery technologies are increasingly using their platforms on their own behalf, to create products they can out-license or possibly market themselves. Now content--getting the molecules to be delivered--is an issue.
BioPharmaceutical Strategy

An Emerging Biotech Customer Base Helps Drug Delivery Firms Balance Risks

When Inhale Therapeutic Systems bought Shearwater, a provider of PEG (polyethylene glycol) technology and development services, it did so to extend its drug delivery capabilities beyond particle-based formulations. But another part of the rationale was to jigger its mix of programs to include both near- and longer-term projects, and to achieve a balance of high- and low-risk projects. As evidenced by its recent spate of deal announcements, the emerging deal-making power of small and mid-sized companies is helping Inhale accomplish those goals.
BioPharmaceutical Strategy

Inhale Chooses the Service Path

Drug delivery has seen plenty of acquisitions-but they represent two basic philosophical approaches, represented most recently by Johnson & Johnson's purchase of Alza and Inhale's acquisition of two privately-held firms, Bradford and Shearwater. The basic question: can a service model bring significant returns to a large shareholder base or will Alza's evolution into a product company define the way forward for the industry?
BioPharmaceutical Business Strategies

Skyepharma:Trying To Take Off From a Short Runway

Since 1998, through a series of inexpensive acquisitions, SkyePharma has assembled a wide range of drug delivery technologies, positioning itself as a one stop shop. But the company still has to convince both its customers, and its investors, that it has not sacrificed quality for quantity.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Respiratory, Pulmonary
  • Alias(es)
  • Bradford Particle Design Ltd.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Nektar Therapeutics
  • Senior Management
  • Contact Info
  • Nektar UK
    Phone: (44) 0 1274 305540
    69 Listerhills Science Pk.
    Campus Road
    Bradford, BD7 1HR
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register